A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
NextPoint Therapeutics, Inc.
Study ID
NCT06240728
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Malignant Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • NPX887 — DRUG
    NPX887 will be administered by IV infusion every 3 weeks until documented disease progression or participant withdrawal for up to 2 years

Study Details

NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to learn whether NPX887 is safe and tolerable and shows a preliminary efficacy in participants with B7-H7 (HHLA2) expressing tumors at selected dose(s). The main questions it aims to answer are: * what is an appropriate dose to be given to participants? * are the side effects of treatment manageable? * what is the preliminary anti-tumor activities? Participants who are treated will receive an intravenous (IV) infusion of NPX887 if their disease has not progressed, and be closely monitored by the treating physicians.

Key Dates

Start date
Jan 22, 2024
Status verified
Jun 2025
Primary completion
Aug 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
144 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: NPX887 Treatment
    Participants will receive NPX887 by IV infusion every 3 weeks.

Primary Outcome Measure

Incidence of dose limiting toxicity (DLT) [ Time Frame: From first dose through 21 days ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
Johns Hopkins University Sidney Kimmel Comprehensive Cancer CenterBaltimoreMaryland21287-
Beth Israel Deaconess Medical Center (BIDMC)BostonMassachusetts02215-
Albert Einstein Medical College Montefiore Medical CenterThe BronxNew York10461-
MD Anderson Cancer CenterHoustonTexas77030-
Next OncologySan AntonioTexas78229-
NEXT Oncology-FairfaxFairfaxVirginia22031-

Find similar trials in Baltimore, MD

By research site
Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center· Baltimore, MDBeth Israel Deaconess Medical Center (BIDMC)· Boston, MAAlbert Einstein Medical College Montefiore Medical Center· The Bronx, NYMD Anderson Cancer Center· Houston, TXNext Oncology· San Antonio, TXNEXT Oncology-Fairfax· Fairfax, VA

Related Studies